Log in to save to my catalogue

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated rec...

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated rec...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2118222831

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

About this item

Full title

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

Publisher

United States: Public Library of Science

Journal title

PloS one, 2018-10, Vol.13 (10), p.e0204973

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription. Onapristone is active in multiple preclinical models and two prior studies demonstrated promising activity in patients with breast cancer. We conducted a study of extended release (ER) Onapristone to determine a recommended dose and explore...

Alternative Titles

Full title

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_2118222831

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2118222831

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0204973

How to access this item